Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
The latest filing no longer states the doubt (first flagged Aug 10, 2026).
View the 10-Q filed Nov 13, 2026Conference · 2026-11-17
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Hi, everyone. This is Phoebe Tan, and I work with Akash Tawari at Jefferies. Today, I have the pleasure of hosting Jade Bio, and I'll pass it over to Tom, the CEO, and Andrew, the president of R&D, for intro remarks. Great.
Thanks so much for hosting us, Phoebe, and the whole Jefferies team. It's great to be here in London. Yeah, just a quick overview into Jade. We're a company focused on developing best-in-class therapies across a number of different autoimmune diseases. Our lead program is Jade 101. It's an anti-April therapy targeting IgA nephropathy at the outset. Really exciting program designed for ultra-high affinity binding to April and a half-life extension to have long duration of action. We released some data in June this year on a Phase I trial in healthy volunteers, which gave us conviction on a best-in-class approach to the disease. We showed really deep and robust reductions of IgA in the disease, more than has seen with any other first-generation agent, and those deep, robust reductions in IgA was actually sustained for a 12-week period, giving us confidence we'll have extended dosing to provide really optimal dosing for patients and minimize treatment burden for them, aiming to have an acute 12-week dose. We started at Phase 2 around the same time, and so we're moving rapidly towards a Phase 2 readout. We've guided that we're going to provide data in the second quarter of next year, but we're not waiting for that data to initiate a Phase 3. We've actually recently updated our guidance to say we'll initiate the Phase 3 trial in IGA nephropathy this quarter, So moving extremely quickly towards registrational data and marketing approval there, potentially. So that's a very exciting program. Our second program is called Jade 201. It's a BAF receptor targeting antibody. It's apheucosylated. It has a very exciting mechanism of action for B cell depletion. We're aiming to get TCE-like efficacy in terms of B cell depletion, But do it without some of the cytokine release syndrome effects that you do see with TCEs. This program is really following in the footsteps of Ionalumab, which is a program that's at Novartis, currently in a number of different Phase 3s, had positive data in Sjogren's last year and is heading towards approval. 201 actually improves upon that profile by having a longer duration of action, So potentially providing benefits of better coverage of the target and better dosing for patients as well. Currently in a rheumatoid arthritis trial with that agent, aiming to read out data in 2027. Our third program, J301, and then we'll pass it back to you for questions, is newly disclosed. It's targeting interferon beta. We'll initially develop that in a disease called dermatomyositis, which is a severe disease that causes neuromuscular and skin complications for patients. We're about to enter a phase one study for that in healthy volunteers, aiming to have data on that in the second half of 2027, and that's a really exciting opportunity where potentially we have a best-in-disease profile there for that asset. So it's three really exciting assets that we're looking to have We're going to have readouts next year on.
Perfect. Thank you for the intro. So just starting with Jade 101, you'll have phase two Juniper data, Q2, 2027. So first, I guess, what magnitude and durability of proteinuria reduction do you consider a win here and very competitive versus benchmarks? And two, in terms of the market, we have a lot of different... Players coming into the IGAN market, so where do you think key differentiation for 101 comes into play?
Yeah. Andrew, why don't you take the expectations around the Juniper study, and then I'll take the differentiation.
Yeah, the Juniper trial is a relatively small 30-patient open-label IGAN study. Our goal with Jade 101 is to provide the full disease-modifying benefit of B cell modulation with a Q12-week maintenance dosing interval to deliver infrequent dosing to this young, otherwise healthy IGAM patient population needing lifelong therapy potentially for decades. Because the study is relatively small in sample size, we don't want to anchor quantitatively too much on a specific reduction in proteinuria, just given the biologic variability of proteinuria In a small sample size, but it's really the totality of the data to replicate the rapid and deep IgA reductions that we observed in the healthy volunteer study, accompanied by depletion of pathogenic GDIGA1, and then proteinuria reductions in the ballpark of the first-generation agents, which have typically been around 50% or so. And if we can do that and maintain it with a Q12-week dosing interval, we think we'll have an exceptional profile that's differentiated to move forward. Based on the phase one data, we do see more rapid and deeper reductions in IgA, and we think that has the potential to translate to earlier reductions in proteinuria than the first-generation agents, And particularly the potential to deliver more patients back to within the target ranges from the KDGO guidelines below 0.5 grams per day and preferably below 0.3 grams per day.
Yeah, so I think you covered the main points on differentiations, but we think IGAN is a very large market size. There's about 170,000 patients in the U.S. alone. 60 to 75 percent of those are above half a gram of proteinuria a day, which really defines those patients at risk of disease progression and are eligible for this class of therapies. So we believe in the U.S. alone it's a $20 billion-plus market opportunity. The first-generation agents, Cibiprinlimab, which is a selective anti-April, and then Vera Zetacacept have recently been approved and are off to very good launches, really showing the demand out there in the market for these novel medications. But as Andrew described, we think we can really positively differentiate from those agents, first of all, by being selective on April, which we think is really the pathogenic driver of the disease. Second, on really capturing that efficacy by having an ultra-potent molecule that allows to have those really deep reductions in IgA that will translate into really robust levels of protein area reduction and get more patients into the target zone. And then, as Andrew also pointed out, these patients are typically diagnosed fairly young in their 20s and 30s, and their lifetime probability of having disease progression and kidney function loss is extremely high, so they need lifelong therapy. So we believe having those 12-week dose interval really control their disease with only four injections a year will be a really big differentiator versus the competition. So we feel really confident we've got a best in disease molecule, which will capture a significant portion of that share.
Great. And then in terms of how much data we'll get from the readout, can you just... Kind of describe how much we'll get, and then should we expect a press release or data at a medical conference, maybe ERA?
Yeah, we have guided on initial interim analysis of that study in Q2 of next year, so ERA does make a lot of sense, typically in June, so that would be a likely venue for presentation. We do like to present at medical conferences. This Phase II data is really not decision-making for the Phase III, as we plan to initiate that before the end of this year, but is really to be able to generate data for external disclosure, particularly for investigators of that Phase III trial, to drive enthusiasm for enrollment to a medical conference is very helpful from that perspective. We initiated enrollment in May of this year, so the data set in Q2 of next year, We'll include those initial patients out through about nine months of treatment, and then increasing numbers of patients at earlier time points. We haven't provided blow-by-blow updates on enrollment in that study, but we do think we'll have a very meaningful data set in Q2 of next year.
Perfect. And then moving on to the phase three. So you've planned to initiate that, this Q4, prior to reading out your phase two. So number one, what is driving the confidence here? Number two, how much time are you saving by, you know, starting it now rather than waiting for the phase two to read out? And number three, has the FDA sort of required seeing any interim or any initial data from your phase two that kind of gave you and the FDA confidence to move forward with the phase three?
Yeah, we have a lot of confidence in our regulatory strategy. There was a meeting with the National Kidney Foundation earlier this year where the FDA really showed that they recognized the need to have really shorter placebo-controlled periods in the Phase III trials. Historically, all the Phase III trials in IGAN have been two-year placebo-controlled trials, but they realized in the setting of these new therapies that are becoming available, it's not really ethical to keep patients on placebo for two years, and in fact, probably not It's not feasible, actually, to ask a patient to recruit for a trial like that, so they expressed a willingness and actually provided some written guidance to sponsors of that meeting, really saying that they're open to a 52-week trial for proteinuria and then EGFR to support full approval, so we feel really confident about that strategy to move forward into the phase three and to do it aggressively. Absolutely. We think with this molecule, like, we will save a significant amount of time. I think if we waited for a robust readout of a Phase II, first of all, we would have had to make the Phase II larger to really power it better than what we have now. And then we'd probably have to read it out for a longer period of time to enable really some decision-making around that. But we feel so confident with the Phase I, that IGA reduction. What we've seen with all the first-generation agents is the PK and PD from the Phase 1 has translated perfectly in what you anticipate seeing in patients, so that Phase 1 data gave us full confidence that we have characterized the profile, really understand the dose and the dose interval, and support moving forward really, really quickly.
Perfect. And I guess in terms of what, is there anything in the phase two that could change what you do in the phase three? Is there flexibility in what you could adjust accordingly?
Yeah, we don't think the phase two is informative for phase three design. As Tom mentioned, we have high confidence in the healthy volunteer data, the PKPD modeling, and the clinical trial simulations that have supported the design of phase three. And the phase two is really for external disclosure of data. It's not powered in a way to provide information for phase three design, and the phase three would be well initiated by the time we have sufficient data from that study.
And so I guess when the phase two does come out, what do you want us to be focusing on?
I think it's really the totality of the data. What's great about the APRIL mechanism of action is it's so biomarker-rich and so consistent between free APRIL suppression, IGA, GDIGA reduction, large reductions in proteinuria, high rates of hematuria resolution, and then most importantly, EGFR stabilization. So truly disease-modifying. So it's the totality of connecting those dots, consistent with the magnitude of treatment effects that we've seen with the first-generation agents, with a Q12-week dosing interval. As we've mentioned, we think that would be a very exciting profile for eye care patients.
Great. And then just thinking about XUS, so you have this aligned with FDA in the U.S., how should we be thinking about XUS, and would they maybe require a two-year time point?
Yeah, we haven't had extensive interactions with ex-U.S. regulators, so we don't completely know the answer to that, to be totally transparent. What we have seen historically is a lot of the other markets, the big markets like Europe do, tend to follow what the FDA does over time. So we will have to engage with them over time to understand if this same trial design would support approval there.
And then just in terms of market uptake, I know the convenience factor, but do you think that having not two-year EGFR will impact anything while the other agents will have that?
Well, we should still be able to see two-year EGFR because we will run the patients out to the two-year time point. It's just the patients on placebo will cross over at the one-year point. So we will still generate that data. So we feel like that will be supportive of commercialization.
Okay, perfect. Moving on to Jade 201, your anti-bath. So you have your phase one in RA reading out in 2027. How much data will we get and what sort of data will we see in the top line that will give you confidence to move forward into the phase two?
Yeah, the phase one study design is a single-ascending dose study in RA patients with six-dose cohorts, starting relatively low in dose with enhanced effector function, B-cell depleter, and steadily escalating up through therapeutic exposures, randomized five-to-one active to placebo per cohort. But, uh, it's... Primary focus is on safety tolerability, pharmacokinetics, but it's also, like Jade 101, a very biomarker-rich, first-in-human study. We'll be able to measure the depth and duration of B cell depletion and follow those profiles, along with a direct measure of BAF receptor occupancy, Which is the dual mechanism of action, not just depleting B cells, but binding and blocking the BAF receptor to get tissue depletion of B cells at the site of tissue injury and autoreactivity. And it's that data set that will help us understand the dosing profile of Jade 101 to provide deep and sustained B cell depletion and receptor coverage as we move on into phase two. We would expect a robust data set, not just at those low initial doses that support dose escalation, but through the therapeutic exposures in our disclosure of the interim analysis of that in 2027.
Great. And then do you, is there a bar for the B-cell depletion and the BAP receptor occupancy that you want to see?
Yeah, we have a nice benchmark with Ionalumab that did a first-in-human study also in rheumatoid arthritis patients, so directly comparable, where they explored a very wide dose range. And what they observed is very deep B-cell depletion of CD19-positive B-cells, essentially complete depletion of circulating B-cells. Our goal would be to sustain that for an extended duration of action relative to ionalumab due to the engineering of half-life extension into J-201's differentiated profile. We also expect to be able to deliver 100% BAF receptor occupancy, which is important for the second mechanism of action to block the pro-survival, pro-proliferative, pro-inflammatory signal of BAF in remaining B cells that are not able to be depleted by ADCC-mediated effective function, so especially those tissue B cells. And again, we'd like to sustain that receptor occupancy for an extended duration relative to Ionalumab. Ionalumab has very favorable pharmacologic properties. It has high affinity binding to the BAF receptor. It's a very potent B-cell depleter, but its one clinical limitation was a relatively short human half-life of only 10 days. In non-human primates, we doubled the half-life of J2O1 and expect to see that play out in a first-in-human study with extended duration of B-cell depletion and receptor occupancy.
So compared to Ionalumab, do you expect longer convenience, but do you expect better efficacy as well there?
So it is possible. So Ionalumab ran two dose schedules in their Sjogren's study, their phase three, that a Q4 week and a Q12 week. And it looks like the Q12 week was really designed more around the PD effects of B cell depletion. But the Q4 week was to have near full receptor occupancy at the population level. And it was clear the Q4 week was superior to the Q12 week, and actually they're only taking the Q4 week forward for registration. So we do believe that there's a possibility with more complete receptor occupancy across all patients for a longer time point that you could potentially get to better levels of clinical activity on top of that better convenience for patients as well.
Okay, perfect. And then based on your phase one, it sounds like you're also going to explore other indications. So what do you want to see that might indicate different indications? And is there anything high on the list, like ITP or Sjogren's, that you might be looking forward to?
Yeah, this is an exciting opportunity. There's 23 different autoimmune indications that we've looked at for J201. Anywhere where rituximab is standard of care, this is where we believe we could get better levels of clinical activity with more convenient dosing. So clearly the six indications where inalumab has gone are all of interest, so Sjogren's is one, although it's a big development plan, so we may look for a partnership to support something like Sjogren's. But, as you mentioned, there are smaller indications, like ITP, there's some first-line data from Inalivab reading out next year, so we'll use that to inform our indication strategy. There's also a number of areas where Novartis didn't go for probably strategic or pipeline prioritization reasons that are more focused and would enable a company like us to go after them. So, things like Anka-associated vasculitis or primary membranous nephropathy are really interesting areas. So, as we see our data set emerge, we really understand what the profile is and get a few more readouts from competitors, then we'll make that decision and talk about our path forward.
And so, just to confirm for RA, you plan to go alone and then potentially combine, or pardon.
So, thanks for asking, actually. Just to clarify, actually, RA is not likely to be one of our lead indications. It's more like a healthy volunteer surrogate, although it is on our list of life cycle management indications, but it's likely, A bigger development plan that we want to do for our lead indication.
Okay, got it. And then positioning and differentiating against other agents that are not, you know, anti-BAP. How do you see it playing out against anti-CD20s, FCRNs, other B-cell directed agents?
Yeah, we think that this mechanism is actually right in a sweet spot where the CD20s and the CD19s, they have this limitation that when they rapidly reduce B cells, you get this compensatory increase in BAF, which is, as Andrew mentioned, a pro-survival, pro-stimulatory signal that causes repopulation. So with J201, you're blocking that, so you're getting that dual mechanism of action, so we should have better levels of clinical activity than the CD19s and the CD20s. This is sort of approaching what you would get with a T-cell engager, sort of those robust levels of depletion, but without the toxicity of those T-cell engagers where you are potentially initiating some cytokine reactivity syndrome or even some liver issues. So we feel like it's a really nice mechanism between those agents.
Perfect. And I was talking to Akash the other day, and he had mentioned maybe some co-formulation with your antipath. Is that a potential on the table?
So it's something we're very intrigued by. No concrete plans yet. But if you look at an indication like Sjogren's, Otsuka is actually taking Cibiprinlimab, which is an anti-April, a selective anti-April, into Sjogren's. They're currently in a phase two, and that data reads out probably in the first half of next year. And so that would give us a glimmer and an understanding as APRIL driving any disease activity in Sjogren's. And we already know that 201 will work in Sjogren's based on the ionalumab data. So it could potentially offer an opportunity to combine the two to see if you could get increased levels of clinical activity. And if that's the case, there's likely other indications that would benefit from a best-in-class APRIL along with a best-in-class BAFR to combine to provide benefit. But we're still monitoring that and making a decision if we're going to go forward with that or not.
So timelines will depend on the readout? Perfect. And then on Jade 301, your interferon beta, you also have a phase one that's going to read out next year, second half, in Healthy Volunteers. What human half-life and bioavailability and exposure would you want to see to validate that?
Yeah, so Jade 301 is an optimized, potentially best-in-class anti-interferon beta, neutralizing monoclonal antibody, really following in the footsteps of Dazukaiba from Pfizer, which has demonstrated really compelling phase 2 proof of concept by targeting interferon beta, both on the muscle and skin components of the disease, very differentiated on the skin benefit relative to other mechanisms of action, which is the most refractory to conventional treatments. The skin component includes painful, itchy, disfiguring rashes. 50% of patients are on opioids to manage their pain, and it results in sleeplessness and fatigue to contribute to poor quality of life. So really excited about the mechanism of action to deliver best in disease benefit across both muscle and skin. The one limitation of Dazukaibat is that it has low sub-Q bioavailability, and as a result, has to be administered at 600 milligrams IV every four weeks. J301 is a de novo monoclonal antibody with... Higher binding affinity and higher functional potency than Dazukaibat, about three to five-fold better in blocking interferon beta-mediated signaling. In addition, we incorporated YTE half-life extension into the FC and observed a three-fold longer half-life in non-human primates of around 30 days. Typically, the non-human primate half-life translates about two to four-fold longer in humans, which would put you in the 60 to 90-ish days, substantially longer than the 20 or so day human half-life that Dazu Kaibat administered. We have developed a subcutaneous formulation to take into the clinic, so plan to administer the phase one healthy volunteer study with sub-Qs. So we think a differentiated profile from Dazukaibar would simply be transitioned from IV to sub-QE with the potential for extended dosing intervals based on the extended half-life that we observed in phase one.
Great, and do you expect any efficacy benefit as well, or mainly the convenience?
There's limited dose range finding by Dazukaibar in phase two. Only a single dose was taken into the muscle predominant disease, which requires higher exposures given the limited antibody distribution to the muscle. So it's not clear if they've left efficacy on the table, but we do think with Jade 301's profile, if we target a similar C-trough to Dazu-Kaibat with a three to five fold times more potent molecule, we'll be able to capture at least the efficacy that Dazu-Kaibat delivered with the potential to get any additional efficacy that they're not capturing based on their dosing schedule.
And we do think that's upside. Just going from an IV to a sub-Q should be very, very differentiating.
That makes sense. And then just lastly, based on healthy volunteers seem to have limited direct interferon beta target engagement data. So how certain will you be in your dosing from your phase one?
Yeah, it's virtually undetectable interferon beta in a healthy volunteer. So it's not a biomarker-rich phase one study, although we will do some ex vivo It's also exploratory biomarker work to gain confidence in the mechanism of action. It's largely a PK study, so really being able to understand via subcutaneous administration how can we match that Dazukaibat trough will give us the confidence that we can at least match that efficacy with a sub-Q dosing profile.
Perfect. We're out of time. Thank you so much.
Great. Thank you.